Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease.
The last earnings update was 55 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Algernon Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Algernon Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Algernon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Algernon Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Algernon Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Algernon Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Algernon Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Algernon Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Algernon Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Algernon Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Algernon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Algernon Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Algernon Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Algernon Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer at Algernon Pharmaceuticals Inc. (f.k.a. Breathtec Biomedical Inc.) since March 1, 2018. Mr. Moreau has been the Chief Executive Officer at NASH Pharmaceuticals Inc., since December 2017. Mr. Moreau has been Consultant of RISE Life Science Corp. (f.k.a. Luminor Medical Technologies Inc. and Miraculins Inc.) since April 21, 2016 and served as its Chief Executive Officer and President from February 1, 2007 to April 21, 2016. Mr. Moreau served as Vice President of Business Development at RISE Life Science Corp. since March 2006 and as a Non Independent Director from May 30, 2011 to April 21, 2016. He joined RISE Life Science Corp. in March 2006. He served as the President of Advansis Capital Corporation, a privately held Canadian financial services provider. He serves in several senior executive roles in sales and marketing within the telecommunications and manufacturing sectors. He has over 20 years’ experience in the areas of business development, sales, marketing and operations management.
Insufficient data for Chris to compare compensation growth.
Chris's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Algernon Pharmaceuticals management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Michael S. Sadhra
CFO & Director
Vice President of Corporate Development & Communications
Chief Science Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Algernon Pharmaceuticals board of directors is about average.
Board of Directors
Michael S. Sadhra
CFO & Director
Member of Medical & Scientific Advisory Board
Member of Medical & Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Introducing Algernon Pharmaceuticals (CNSX:AGN), The Stock That Slid 64% In The Last Three Years
But long term Algernon Pharmaceuticals Inc. … Some Algernon Pharmaceuticals investors have already had a taste of the bitterness stocks like this can leave in the mouth. … Of course the long term matters more than the short term, and even great stocks will sometimes have a poor year.
Did Changing Sentiment Drive Algernon Pharmaceuticals's (CNSX:AGN) Share Price Down A Painful 71%?
Algernon Pharmaceuticals didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … It seems likely some shareholders believe that Algernon Pharmaceuticals will significantly advance the business plan before too long. … When it last reported its balance sheet in November 2018, Algernon Pharmaceuticals had net cash of CA$1.1m.
Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in February 2019. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.